Solid forms of tyrosine kinase inhibitors, process for the preparation and their pharmaceutical composition thereof
The present invention generally relates to solid forms of tyrosine kinase inhibitors, in particular combinations of tyrosine kinase inhibitors with anti-oxidative acids, processes for its preparation and a pharmaceutical compositions containing the same.
1. A pharmaceutical composition comprising an amount of a solid form of imatinib or gefitinib, and an amount of caffeic acid,
wherein the amount of the imatinib or the gefitinib in the solid form is effective in inhibiting tyrosine kinase, and the amount of caffeic acid in the solid form is effective in improving the solubility of the imatinib or the gefitinib in water and reducing free radicals, and
wherein the solid form of gefitinib and caffeic acid is characterized by a ratio of 2:1, an X-Ray diffraction pattern of FIG. 1 , and the solid form of gefitinib used in the composition has a D50 and D90 of less than about 10 microns,
wherein the solid form of imatinib and caffeic acid is characterized by a ratio of 1:1, an X-Ray diffraction pattern of FIG. 7 , and the solid form of imatinib used in the composition has a D50 and D90 of less than about 10 microns, or
wherein the solid form of imatinib and caffeic acid is characterized by a ratio of 1:2, an X-Ray diffraction pattern of FIG. 9 , and the solid form of imatinib used in the composition has a D50 and D90 of less than about 10 microns.
2. The composition of claim 1 , wherein the solid form of imatinib and caffeic acid having the ratio of 1:1 is further characterized by the differential scanning calorimetric thermogram of FIG. 8 , and wherein the solid form of imatinib and caffeic acid having the ratio of 1:2 is further characterized by the differential scanning calorimetric thermogram of FIG. 10 .
3. The composition of claim 1 , wherein the solid form of gefitinib and caffeic acid is characterized by the differential scanning calorimetric thermogram of FIG. 2 .
4. A process for preparing a solid form of a pharmaceutical composition comprising imatinib or gefitinib, and an amount of caffeic acid, comprising:
a) providing a mixture or solution comprising the imatinib or gefitinib either in free base or a salt form, and the caffeic acid; and
b) isolating the solid form of a composition comprising the imatinib or gefitinib and caffeic acid from the mixture or solution,
wherein the amount of the imatinib or the gefitinib in the isolated solid form is effective in inhibiting tyrosine kinase, and the amount of caffeic acid in the isolated solid form is effective in improving the solubility of the imatinib or the gefitinib in water and reducing free radicals, and
wherein the isolated solid form of gefitinib and caffeic acid is characterized by a ratio of 2:1, an X-Ray diffraction pattern of FIG. 1 , and the solid form of gefitinib used in the composition has a D50 and D90 of less than about 10 microns,
wherein the isolated solid form of imatinib and caffeic acid is characterized by a ratio of 1:1, an X-Ray diffraction pattern of FIG. 7 , and the solid form of imatinib used in the composition has a D50 and D90 of less than about 10 microns, or
wherein the isolated solid form of imatinib and caffeic acid is characterized by a ratio of 1:2, an X-Ray diffraction pattern of FIG. 9 , and the solid form of imatinib used in the composition has a D50 and D90 of less than about 10 microns.
5. A process for preparing a pharmaceutical composition comprising a solid form of imatinib or gefitinib, and an amount of caffeic acid, comprising:
a) providing a solid form of imatinib or gefitinib having a micronized D50 and D90 particle size of less than about 10 microns;
b) mixing an amount of the micronized solid form of imatinib or gefitinib with an amount of caffeic acid; and
c) forming the pharmaceutical composition from the mixture,
wherein the amount of the imatinib or the gefitinib in the composition is effective in inhibiting tyrosine kinase, and the amount of caffeic acid in the composition is effective in improving the solubility of the imatinib or the gefitinib in water and reducing free radicals, and
wherein the mixture of gefitinib and caffeic acid is characterized by a ratio of 2:1, and an X-Ray diffraction pattern of FIG. 1 ,
wherein the mixture of imatinib and caffeic acid is characterized by a ratio of 1:1, and an X-Ray diffraction pattern of FIG. 7 , or
wherein the mixture of imatinib and caffeic acid is characterized by a ratio of 1:2, and an X-Ray diffraction pattern of FIG. 9 .